| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/07/2002 | WO2002018321A2 Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors |
| 03/07/2002 | WO2002018320A2 INHIBITORS OF α4 MEDIATED CELL ADHESION |
| 03/07/2002 | WO2002017967A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | WO2002017949A2 Novel functions for dp214 |
| 03/07/2002 | WO2002017945A1 Efficient method for producing compositions enriched in anthocyanins |
| 03/07/2002 | WO2002017944A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
| 03/07/2002 | WO2002017943A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain |
| 03/07/2002 | WO2002017942A1 Use of a composition comprising an extract of pollen for the treatment of irritability |
| 03/07/2002 | WO2002017941A1 Use of a composition comprising an extract of pollen for the treatment of edema |
| 03/07/2002 | WO2002017940A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria |
| 03/07/2002 | WO2002017933A1 Trace elements |
| 03/07/2002 | WO2002017927A1 Method for treating erectile dysfunction and increasing libido in men |
| 03/07/2002 | WO2002017914A2 Fused pyrrolocarbazoles against inflammation |
| 03/07/2002 | WO2002017906A1 Composition and method for treatment of hypertriglyceridemia |
| 03/07/2002 | WO2002017892A2 Water-dispersible encapsulated sterols |
| 03/07/2002 | WO2002017891A2 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency |
| 03/07/2002 | WO2002017735A2 Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate |
| 03/07/2002 | WO2002017734A2 Materials and methods for the treatment or prevention of obesity |
| 03/07/2002 | WO2002017732A2 Efficient method for producing compositions enriched in anthocyanins |
| 03/07/2002 | WO2001094420B1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 03/07/2002 | WO2001093911A3 Macromolecular drug complexes and compositions containing the same |
| 03/07/2002 | WO2001090103A9 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 03/07/2002 | WO2001082867A3 A core formulation |
| 03/07/2002 | WO2001077100A3 Benzoamide piperidine compounds as substance p antagonists |
| 03/07/2002 | WO2001062765A3 Small molecule modulators of g protein-coupled receptor six |
| 03/07/2002 | WO2001062236A3 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| 03/07/2002 | WO2001058956A3 Antibodies that bind human interleukin-18 and methods of making and using |
| 03/07/2002 | WO2001057233A3 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides |
| 03/07/2002 | WO2001057022A3 Pyrazole compositions useful as inhibitors of erk |
| 03/07/2002 | WO2001056983A3 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
| 03/07/2002 | WO2001055692A3 Neurosteroids as markers for alzheimer's disease |
| 03/07/2002 | WO2001055219A3 scsCNTFR/NNT-1 FUSION PROTEIN |
| 03/07/2002 | WO2001053468A3 Lipid metabolism enzymes and polynucleotides encoding them |
| 03/07/2002 | WO2001049261A3 Stable aqueous deoxyfructosazine solution |
| 03/07/2002 | WO2001046231A3 Polynucleotides and polypeptides encoded thereby |
| 03/07/2002 | WO2001032888A3 Human transferase molecules |
| 03/07/2002 | WO2001031008A3 Human and rat fgf-20 genes and gene expression products |
| 03/07/2002 | WO2001023377A3 Polymorphic salt |
| 03/07/2002 | WO2001021163A3 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/07/2002 | WO2001015673A3 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
| 03/07/2002 | US20020028953 Process for preparing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-acetic acid |
| 03/07/2002 | US20020028940 Also benzimidazolyl and imidazo(4,5-b)pyridinyl-substituted; amides; antiatherosclerotic; reduces smooth muscle cell proliferation as well as reduction in lipoproteins, cholesterol and triglycerides |
| 03/07/2002 | US20020028921 Pluraflavins and derivatives thereof, process for their preparation and use thereof |
| 03/07/2002 | US20020028851 Guanylhydrazones and their use to treat inflammatory conditions |
| 03/07/2002 | US20020028848 Administering orally 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE); anticoagulants; cardiovascular, respiratory, gastrointestinal, nervous and psyiatric disorders; autoimmune disease; antiinflammatory agents; bactericides; viricides |
| 03/07/2002 | US20020028835 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 03/07/2002 | US20020028830 Treating proteinuria and swollen lymph node symptoms by administering an effective dose of a vitamin D analog to a patient on a diet which includes a calcium intake level of >800mg/day per 160 pound patient |
| 03/07/2002 | US20020028828 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | US20020028826 HMG-CoA reductase inhibitors and method |
| 03/07/2002 | US20020028821 Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors |
| 03/07/2002 | US20020028817 Platelet derived growth factors (PDGF); 1,2-dimethyl-6-(2-thiophene)imidazolo(5,4-g)quinoxaline preparations for example; use treating proliferative malignant and non-malignant diseases; stents |
| 03/07/2002 | US20020028815 Novel multicyclic compounds and the use thereof |
| 03/07/2002 | US20020028812 Phenylalanine derivatives |
| 03/07/2002 | US20020028808 Use of potassium channel agonists for the treatment of cancer |
| 03/07/2002 | US20020028797 Therapy for metabolism diseases; dietetics; antidiabetic agents |
| 03/07/2002 | US20020028796 Adjustment mineral concentration |
| 03/07/2002 | US20020028793 Antilipemic agents, anticholesterol agents, anticoagulants |
| 03/07/2002 | US20020028775 Using mixture of flavonoids, cytochrome inhibitor, sugar, phosphate in carrier |
| 03/07/2002 | US20020028772 Modulation of metabolism |
| 03/07/2002 | US20020028769 Method for preparing zinc-oligopeptide easily absorbable by the human body |
| 03/07/2002 | US20020028239 Tablet composition |
| 03/07/2002 | US20020028207 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 03/07/2002 | US20020028201 Element A, which is a plastic with a group derived from a carboxy acid (e.g., an acrylate polymer), is hydrogen bonded to an element B (e.g., polyalkylene glycol; coupling physiologically and/or pharmacologically active substances |
| 03/07/2002 | US20020028190 Compositions of non-ionic block copolymers to treat autoimmune, proliferative, and inflammatory diseases and methods of use thereof |
| 03/07/2002 | DE10041574A1 Chromenonderivate Chromenonderivate |
| 03/07/2002 | DE10041423A1 Biphenylderivate Biphenyl |
| 03/07/2002 | CA2746787A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | CA2424146A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
| 03/07/2002 | CA2424026A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria |
| 03/07/2002 | CA2424011A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain |
| 03/07/2002 | CA2421893A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | CA2421524A1 Materials and methods for the treatment or prevention of obesity |
| 03/07/2002 | CA2421055A1 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | CA2420906A1 Use of a composition comprising an extract of pollen for the treatment of edema |
| 03/07/2002 | CA2420869A1 Compounds having activity as inhibitors of cytochrome p450rai |
| 03/07/2002 | CA2420835A1 Composition and method for treatment of hypertriglyceridemia |
| 03/07/2002 | CA2420832A1 Methods and reagents for protease inhibition |
| 03/07/2002 | CA2420823A1 Use of a composition comprising an extract of pollen for the treatment of irritability |
| 03/07/2002 | CA2420652A1 Vertebrate intestinal protein which absorbs cholesterol, and the use of this protein for identifying inhibitors of intestinal cholesterol transport |
| 03/07/2002 | CA2420591A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | CA2420363A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | CA2420178A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
| 03/07/2002 | CA2420122A1 7-oxo pyridopyrimidines |
| 03/07/2002 | CA2419699A1 Gem-substituted .alpha. v .beta. 3 integrin antagonists |
| 03/07/2002 | CA2419255A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| 03/07/2002 | CA2419249A1 Water-dispersible encapsulated sterols |
| 03/07/2002 | CA2416740A1 Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors |
| 03/06/2002 | EP1184465A2 Method for diagnosing polymorphisms in human MCT-1 and drugs related to such polymorphisms |
| 03/06/2002 | EP1184454A2 Nav2 channel gene-deficient non-human animals |
| 03/06/2002 | EP1184384A1 1-(Alkyl), 1-((heteroaryl)alkyl) and 1-((aryl)alkyl)-7-pyridin-4-ylimidazo(1,2a)pyrimidin-5(1H)-one derivatives |
| 03/06/2002 | EP1184366A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha(ppar) |
| 03/06/2002 | EP1183351A1 Phospholipid transfer protein |
| 03/06/2002 | EP1183259A2 Azepinoindole derivatives, the production and use thereof |
| 03/06/2002 | EP1183252A1 New pharmaceutically active compounds |
| 03/06/2002 | EP1183247A1 Polycyclic thiazole systems and their utilization as anorectics |
| 03/06/2002 | EP1183245A1 Selective npy (y5) antagonists |
| 03/06/2002 | EP1183241A1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 03/06/2002 | EP1183237A1 Novel antioxidants, preparation methods and uses |
| 03/06/2002 | EP1183229A1 Glucagon antagonists/inverse agonists |
| 03/06/2002 | EP1183074A1 Substituted biaryl ether compounds |